Your browser doesn't support javascript.
loading
Patient and Graft Survival After A1/A2-incompatible Living Donor Kidney Transplantation.
Bisen, Shivani S; Getsin, Samantha N; Chiang, Po-Yu; Herrick-Reynolds, Kayleigh; Zeiser, Laura B; Yu, Sile; Desai, Niraj M; Al Ammary, Fawaz; Jackson, Kyle R; Segev, Dorry L; Massie, Allan B.
Afiliación
  • Bisen SS; Grossman School of Medicine, New York University, New York, NY.
  • Getsin SN; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Chiang PY; Grossman School of Medicine, New York University, New York, NY.
  • Herrick-Reynolds K; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Zeiser LB; Grossman School of Medicine, New York University, New York, NY.
  • Yu S; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Desai NM; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Al Ammary F; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Jackson KR; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Segev DL; Grossman School of Medicine, New York University, New York, NY.
  • Massie AB; Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD.
Transplant Direct ; 8(11): e1388, 2022 Nov.
Article en En | MEDLINE | ID: mdl-36284928
ABO type B and O kidney transplant candidates have increased difficulty identifying a compatible donor for living donor kidney transplantation (LDKT) and are harder to match in kidney paired donation registries. A2-incompatible (A2i) LDKT increases access to LDKT for these patients. To better inform living donor selection, we evaluated the association between A2i LDKT and patient and graft survival. Methods: We used weighted Cox regression to compare mortality, death-censored graft failure, and all-cause graft loss in A2i versus ABO-compatible (ABOc) recipients. Results: Using Scientific Registry of Transplant Recipients data 2000-2019, we identified 345 A2i LDKT recipients. Mortality was comparable among A2i and ABOc recipients; weighted 1-/5-/10-y mortality was 0.9%/6.5%/24.2%, respectively, among A2i LDKT recipients versus 1.4%/7.7%/22.2%, respectively, among ABOc LDKT recipients (weighted hazard ratio [wHR], 0.811.041.33; P = 0.8). However, A2i recipients faced higher risk of death-censored graft failure; weighted 1-/5-/10-y graft failure was 5.7%/11.6%/22.4% for A2i versus 1.7%/7.5%/17.2% for ABOc recipients (wHR in year 1 = 2.243.565.66; through year 5 = 1.251.782.53; through year 10 = 1.151.552.07). By comparison, 1-/5-/10-y wHRs for A1-incompatible recipients were 0.631.966.08/0.390.942.27/0.390.831.74. Conclusions: A2i LDKT is generally safe, but A2i donor/recipient pairs should be counseled about the increased risk of graft failure and be monitored as closely as their A1-incompatible counterparts posttransplant.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transplant Direct Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transplant Direct Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos